Hidradenitis Suppurativa: Clinical Trials

283 trials for Hidradenitis Suppurativa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

127 completed, 55 recruiting, 24 unknown, 23 active not recruiting. 90 Phase 2, 48 Not applicable, 33 Phase 3, 24 Phase 1, 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 290Completed 49, Recruiting 15, Terminated 10, Active not recruiting 8, Unknown 4, Not yet recruiting 2, Withdrawn 2
Not applicable48Completed 22, Unknown 8, Terminated 6, Not yet recruiting 5, Recruiting 5, Active not recruiting 1, Withdrawn 1
Phase 333Completed 17, Active not recruiting 9, Recruiting 3, Terminated 3, Enrolling by invitation 1
Phase 124Completed 11, Recruiting 8, Not yet recruiting 2, Active not recruiting 1, Unknown 1, Withdrawn 1
Phase 411Withdrawn 3, Completed 2, Not yet recruiting 2, Unknown 2, Recruiting 1, Terminated 1
Early Phase 110Completed 4, Recruiting 3, Withdrawn 2, Unknown 1

Follow Hidradenitis Suppurativa: new trials by email Literature Review of Hidradenitis Suppurativa trials Research Report on Hidradenitis Suppurativa

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of SL-325 in Participants With Hidradenitis Suppurativa
SL-325, Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingShattuck Labs, Inc.1502027-01-012026-11-13
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals342026-12-312026-11-10
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals1862026-11-132026-10-20
Early Pathophysiology of Hidradenitis Suppurativa and Prediction of the Risk of Progression: a Prospective Cohort
Biological samples and questionnaires, Analysis of residual skin tissue - Hidradenitis Suppurativa (HS)
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris2002026-11-012026-11-06
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
LOU064, Placebo - Hidradenitis Suppurativa
Phase 1RecruitingNovartis Pharmaceuticals302026-10-292026-11-10
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Olatorepatide, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingRegeneron Pharmaceuticals3002026-10-292026-11-10
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, Eczema/Atopic Dermatitis
Not yet recruitingMedisch Spectrum Twente10002026-10-012026-09-04
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingUniversity of Massachusetts, Worcester402026-10-012026-09-10
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Soquelitinib - Hidradenitis Suppurativa (HS)
Phase 1RecruitingCorvus Pharmaceuticals, Inc.252026-09-172026-10-15
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS)
Phase 2RecruitingHarrison Dermatology102026-09-102026-10-13
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS)
Phase 2RecruitingSpyre Therapeutics, Inc.1502026-09-012026-10-19
The Safety and Efficacy of Roflumilast Foam in HS
Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS)
Phase 2RecruitingBeth Israel Deaconess Medical Center202026-09-012026-07-09
Mediterranean Dietary Intervention for HS
Mediterranean Diet Counseling, Mediterranean Food Support - Hidradenitis Suppurativa
Not applicableNot yet recruitingUniversity of North Carolina, Chapel Hill302026-09-012026-09-02
An Observational Study of Patients With Dermatologic Disease
Vitiligo, Atopic Dermatitis
Not yet recruitingTarget PharmaSolutions, Inc.20000002026-09-012026-09-10
Urinary Bladder Matrix (UBM) Registry
Urinary Bladder Matrix (UBM) Products - Tissue Repair, Soft Tissue Reconstruction
Not yet recruitingIntegra LifeSciences Corporation3002026-08-312026-09-04
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
ORKA-002, Placebo - Hidradenitis Suppurativa (HS)
Phase 2RecruitingOruka Therapeutics, Inc.2002026-08-212026-10-29
Acceptability of MBSR for People With HS
Mindfulness-Based Stress Reduction - Hidradenitis Suppurativa (HS)
Not applicableActive not recruitingUniversity of California, San Francisco172026-08-102026-11-03
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Remibrutinib - Hidradenitis Suppurativa
Phase 3RecruitingNovartis Pharmaceuticals7102026-07-102026-11-09
Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa
Nd:YAG Laser, Alexandrite Laser - Hidradenitis Suppurativa (HS)
Not applicableNot yet recruitingGeisinger Clinic212026-07-012026-04-28
A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
Upadacitinib - Hidradenitis Suppurativa (Acne Inversa)
Phase 2Active not recruitingPeking Union Medical College502026-07-012026-07-27

Showing 20 of 283. Sign in to see all of them.

Narrower conditions

Hidradenitis (27)  ·  Psoriasis (22)  ·  Dermatitis, Atopic (21)  ·  Skin Diseases (19)  ·  Alopecia Areata (11)  ·  Arthritis, Rheumatoid (9)  ·  Vitiligo (9)  ·  Abscess (8)  ·  Acne Vulgaris (8)  ·  Arthritis, Psoriatic (8)  ·  Colitis, Ulcerative (8)  ·  Crohn Disease (8)  ·  Sweat Gland Diseases (7)  ·  Skin Diseases, Bacterial (6)

Broader conditions

Bacterial Infections (283)  ·  Bacterial Infections and Mycoses (283)  ·  Skin Diseases, Infectious (283)  ·  Infections (282)  ·  Skin and Connective Tissue Diseases (282)  ·  Suppuration (278)  ·  Skin Diseases, Bacterial (277)  ·  Sweat Gland Diseases (276)  ·  Skin Diseases (264)  ·  Hidradenitis (256)  ·  Immune System Diseases (33)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Pathologic Processes (29)  ·  Skin Diseases, Papulosquamous (28)  ·  Hypersensitivity (24)

Interventions

Adalimumab (16)  ·  secukinumab (14)  ·  bimekizumab (7)  ·  remibrutinib (5)  ·  sonelokimab (5)  ·  Sodium Chloride (4)  ·  brodalumab (4)  ·  upadacitinib (4)  ·  Blood Specimen Collection (3)  ·  Botulinum Toxins, Type A (3)  ·  Lasers (3)  ·  Lasers, Solid-State (3)  ·  Roflumilast (3)  ·  apremilast (3)  ·  guselkumab (3)

Sponsors

Novartis Pharmaceuticals (21)  ·  AbbVie (15)  ·  Incyte Corporation (12)  ·  Henry Ford Health System (7)  ·  UCB Biopharma SRL (6)  ·  University of Miami (6)  ·  Montefiore Medical Center (5)  ·  MoonLake Immunotherapeutics AG (5)  ·  Boehringer Ingelheim (4)  ·  Florida Academic Dermatology Centers (4)  ·  Janssen Research & Development, LLC (4)  ·  Peking Union Medical College (4)  ·  Rockefeller University (4)  ·  Sanofi (4)  ·  University of California, San Francisco (4)

Countries

United States (161)  ·  Canada (66)  ·  Germany (65)  ·  France (52)  ·  Spain (50)  ·  Poland (45)  ·  Netherlands (39)  ·  Australia (33)  ·  Greece (31)  ·  Italy (29)  ·  Belgium (25)  ·  Bulgaria (25)  ·  Czechia (25)  ·  Denmark (23)  ·  China (22)

Top investigators

Hadar Lev-Tov, MD (5)  ·  Christopher J Sayed, MD (3)  ·  John W Frew, MD (3)  ·  Steven R Cohen, MD, MPH (3)  ·  Antonio Martorell, PhD (2)  ·  Baoxi Wang, Master (2)  ·  Evangelos J Giamarellos-Bourboulis, MD, PhD (2)

Results publications

PMID 27518661, PMID 29380251, PMID 31604104, PMID 36746171, PMID 41248770, PMID 42482599, PMID 42525209, PMID 22236226, PMID 23247938, PMID 32460374, PMID 34252397, PMID 34978076, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 12140476, PMID 14632813, PMID 16918566, PMID 17587838, PMID 19036028, PMID 19185954, PMID 19293006, PMID 19438670, PMID 20039918, PMID 20115947, PMID 20166154, PMID 20227579, PMID 20479297, PMID 23460557, PMID 23904820, PMID 24807602, PMID 25396122, PMID 25640693, PMID 26119625, PMID 26470622, PMID 26579854, PMID 27136622, PMID 27692735, PMID 28027202, PMID 29439003

NIH funding

2025 (9), 2023 (7), 2018 (5), 2019 (3), 2004 (1), 2008 (1), 2015 (1), 2017 (1), K08AR080844 (1), KL2RR031974 (1), R01NR013888 (1), R33AR077495 (1), R61AR087105 (1), UL1RR031975 (1)